No Surprises from the FTSE's Leading Pharma Stocks

AstraZeneca and GlaxoSmithKline both posted third-quarter results that were largely in line with our analyst's expectations

Holly Cook 27 October, 2011 | 5:09PM
Facebook Twitter LinkedIn

Both AstraZeneca (AZN) and GlaxoSmithKline (GSK) reported third-quarter results that largely matched our analyst Damien Conover's expectations. He doesn't expect any changes to his fair value estimates for either stock.

For Glaxo, it was strong Cervarix sales helping to offset the loss of Advair's market share that led to the no-surprises results, while at Astra it was strong Crestor sales helping to mitigate generic competition.

Morningstar research suggests both Astra and Glaxo shares are currently fairly valued, carrying as they do 3-star ratings. Read Conover's response to Glaxo's numbers and full investment thesis here, and his results assessment and long-term view of Astra here. Morningstar analysis is available to Premium subscribers.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
AstraZeneca PLC12,110.00 GBX-0.46Rating

About Author

Holly Cook

Holly Cook  is Manager, Morningstar EMEA Websites

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures